Cargando…

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is ass...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084355/ https://www.ncbi.nlm.nih.gov/pubmed/33933206 http://dx.doi.org/10.1016/S0140-6736(21)00676-0

Ejemplares similares

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2020)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Publicado: (2021)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Publicado: (2022)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2023)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
por: Rahhal, Alaa, et al.
Publicado: (2022)

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
por: Wang, Dongsheng, et al.
Publicado: (2021)

Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
por: Lacombe, Karine, et al.
Publicado: (2023)

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
por: Lopes, Renato D, et al.
Publicado: (2021)

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
por: Cohen, Jordana B, et al.
Publicado: (2021)

Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)
por: de Farias, Danielle Leão Cordeiro, et al.
Publicado: (2020)

Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study
por: Karampitsakos, Theodoros, et al.
Publicado: (2021)

Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study
por: Siami, Zeinab, et al.
Publicado: (2023)

Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
por: Malekzadeh, Reza, et al.
Publicado: (2020)

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2020)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
por: Hayward, Gail, et al.
Publicado: (2021)

29. Sustained Recovery in Patients Admitted to Hospital With COVID-19
por: Moestrup, Kasper S, et al.
Publicado: (2021)

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
por: Khanna, Dinesh, et al.
Publicado: (2018)

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial
por: Sekhavati, Ehsan, et al.
Publicado: (2020)

A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan
por: Chiodini, Paolo, et al.
Publicado: (2020)

Tocilizumab for hospitalized patients with COVID-19
por: Afra, Kevin, et al.
Publicado: (2021)

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
Publicado: (2023)

Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials
por: Selvaraj, Vijairam, et al.
Publicado: (2021)

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
por: Ader, Florence, et al.
Publicado: (2022)

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
por: Yu, Ly-Mee, et al.
Publicado: (2021)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Publicado: (2022)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
por: Bégin, Philippe, et al.
Publicado: (2021)

An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial
por: Koga, Tomohiro, et al.
Publicado: (2020)

Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial.
por: Rosales Renteria, Luis Alejandro, et al.
Publicado: (2022)

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial
por: Soin, Arvinder S, et al.
Publicado: (2021)

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
por: Sekine, Leo, et al.
Publicado: (2022)

Safety and efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial
por: Christian, Gnanaraj Johnson, et al.
Publicado: (2023)

Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19)
por: Brodin, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_187safj7evmne79aitr300ceka